Form 8-K · Current Report · Filed 2026-05-06
Revolution Medicines Announces Positive Daraxonrasib Trial Results and Strong Financial Position
Revolution Medicines, Inc. announced its financial results for the quarter ended March 31, 2026, highlighting significant improvements in overall survival for patients with previously treated metastatic pancreatic cancer from the RASolute 302 trial of daraxonrasib. The company also reported strengthened financial position with financings totaling $2.2 billion in gross proceeds. These results mark a major advance for patients and strengthen the company's conviction in its RAS(ON) inhibition strategy across RAS-driven cancers.
- Filer
- Revolution Medicines Inc. RVMD · NASDAQ
- Filed
- Accession
- 0001193125-26-208918
- CIK
- 0001628171
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$147.21
Next session
-3.2%
Since filing
+27.4%
Latest close
$187.53
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVMD reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, RVMD insiders reported 47 Form 4 transactions — net selling of $16.8M.
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Never miss another RVMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.